Cartesian Therapeutics (RNAC) Misses Q1 EPS by 146c
Tweet
Share
E-mailGet Alerts RNAC Hot Sheet
Join SI Premium – FREE
Cartesian Therapeutics (NASDAQ: RNAC) reported Q1 EPS of ($1.46).
For earnings history and earnings-related data on Cartesian Therapeutics (RNAC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- Klarna shares tumble on weak full-year revenue guidance
- La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
